MannKind Corporation

NasdaqGM:MNKD 주식 보고서

시가총액: US$1.9b

MannKind 관리

관리 기준 확인 3/4

MannKind CEO는 Michael Castagna, May2017 에 임명되었습니다 의 임기는 7.5 년입니다. 총 연간 보상은 $ 7.07M, 9.9% 로 구성됩니다. 9.9% 급여 및 90.1% 보너스(회사 주식 및 옵션 포함). 는 $ 15.60M 가치에 해당하는 회사 주식의 0.83% 직접 소유합니다. 15.60M. 경영진과 이사회의 평균 재임 기간은 각각 7.3 년과 4.8 년입니다.

주요 정보

Michael Castagna

최고 경영자

US$7.1m

총 보상

CEO 급여 비율9.9%
CEO 임기7.5yrs
CEO 소유권0.8%
경영진 평균 재임 기간7.3yrs
이사회 평균 재임 기간4.8yrs

최근 관리 업데이트

Recent updates

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Oct 03

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Sep 18
MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

Jul 17
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

MannKind Outperforms As Tyvaso DPI Captures Market Share

May 15

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Mar 02
MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation

Feb 15

MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

Jan 03
MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

May 15
Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Jan 27
MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Mannkind Corporation: Ready For Your Biotech Portfolio

Sep 01

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Aug 19
New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

Aug 09

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

Feb 25

MannKind: A Promising Player In The Inhalable Insulin Market

Feb 08

US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Aug 14
US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Lytham Partners Summer 2021 Investor Conference

Jun 14

MannKind (MNKD) Investor Presentation - Slideshow

Jun 04

MannKind reduces debt by $49.5M and restructures remaining obligations

Apr 26

Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

Feb 22
Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

MannKind to co-promote Thyquidity

Dec 17

CEO 보상 분석

Michael Castagna 의 보수는 MannKind 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

US$22m

Jun 30 2024n/an/a

US$12m

Mar 31 2024n/an/a

US$8m

Dec 31 2023US$7mUS$702k

-US$12m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$47m

Mar 31 2023n/an/a

-US$71m

Dec 31 2022US$4mUS$623k

-US$87m

Sep 30 2022n/an/a

-US$98m

Jun 30 2022n/an/a

-US$88m

Mar 31 2022n/an/a

-US$94m

Dec 31 2021US$4mUS$598k

-US$81m

Sep 30 2021n/an/a

-US$79m

Jun 30 2021n/an/a

-US$86m

Mar 31 2021n/an/a

-US$61m

Dec 31 2020US$4mUS$495k

-US$57m

Sep 30 2020n/an/a

-US$45m

Jun 30 2020n/an/a

-US$44m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$2mUS$511k

-US$52m

Sep 30 2019n/an/a

-US$47m

Jun 30 2019n/an/a

-US$61m

Mar 31 2019n/an/a

-US$71m

Dec 31 2018US$2mUS$500k

-US$87m

Sep 30 2018n/an/a

-US$110m

Jun 30 2018n/an/a

-US$119m

Mar 31 2018n/an/a

-US$131m

Dec 31 2017US$1mUS$459k

-US$117m

보상 대 시장: Michael 의 총 보상 ($USD 7.07M )은 US 시장( $USD 5.34M ).

보상과 수익: Michael 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Michael Castagna (47 yo)

7.5yrs

테뉴어

US$7,068,114

보상

Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...

리더십 팀

이름위치테뉴어보상소유권
Michael Castagna
CEO & Director7.5yrsUS$7.07m0.83%
$ 15.6m
Lauren Sabella
Chief Operating Officer1.7yrsUS$2.74m0.025%
$ 478.2k
David Thomson
Executive VP22.8yrsUS$2.34m0.17%
$ 3.1m
Stuart Tross
Executive VP and Chief People & Workplace Officer7.9yrsUS$2.22m0.22%
$ 4.1m
Christopher Prentiss
Chief Financial Officerless than a year데이터 없음데이터 없음
Sanjay Singh
Executive Vice President of Technical Operations2.1yrsUS$1.12m0.035%
$ 650.2k
Rosabel Alinaya
VP of Investor Relations & Treasury7.3yrsUS$519.59k데이터 없음
John Bedard
Senior Vice President of Worldwide Regulatory Affairs19.1yrs데이터 없음데이터 없음
James McCauley
Chief Commercial Officer7.3yrsUS$921.51k데이터 없음
Burkhard Blank
Executive VP of Research & Development and Chief Medical Officer1.5yrs데이터 없음0.070%
$ 1.3m

7.3yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: MNKD 의 관리팀은 노련하고 경험 (평균 재직 기간 7.3 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Michael Castagna
CEO & Director7.5yrsUS$7.07m0.83%
$ 15.6m
Ronald Consiglio
Independent Director21.1yrsUS$241.73k0.043%
$ 805.2k
Kent Kresa
Chairman Emeritusless than a yearUS$240.64k0.096%
$ 1.8m
Christine Ann Mundkur
Independent Director6yrsUS$226.73k0.010%
$ 188.3k
Michael Friedman
Independent Director20.9yrsUS$229.23k0.0054%
$ 101.6k
Anthony Hooper
Independent Director4.8yrsUS$233.14k0.064%
$ 1.2m
James Shannon
Independent Chairman9.5yrsUS$255.64k0.0089%
$ 166.3k
Sabrina Kay
Independent Director3.9yrsUS$221.73k0.039%
$ 727.8k
Thomas Blevins
Member of Scientific Advisory Board3.3yrs데이터 없음데이터 없음
Steven Binder
Directorless than a yearUS$2.34m0.20%
$ 3.7m
Jennifer Grancio
Independent Director4.7yrsUS$221.73k0.040%
$ 752.7k
Davida Kruger
Member of Scientific Advisory Board3.3yrs데이터 없음데이터 없음

4.8yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 이사회: MNKD 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.